COMMUNIQUÉS West-GlobeNewswire

Après six mois, le DynamX Bioadaptor d’Elixir Medical fait preuve d’une amélioration importante en comparaison des stents à élution médicamenteuse (DES), chez les patients atteints de syndrome coronarien aigu et de lésions complexes
28/10/2024
Après six mois, le DynamX Bioadaptor d’Elixir Medical fait preuve d’une amélioration importante en comparaison des stents à élution médicamenteuse (DES), chez les patients atteints de syndrome coronarien aigu et de [...]
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
28/10/2024
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and [...]
Oxford Treatment Center Leads the Way in Delivering Veteran Ready Care with New PsychArmor Certification
28/10/2024
ETTA, Miss., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oxford Treatment Center has joined a small group of addiction treatment providers across the nation that have achieved Veteran Ready Certification from PsychArmor, a [...]
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
28/10/2024
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY ADDING [...]
AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose
28/10/2024
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET EUROPÉEN COUVRANT JUSQU'EN 2040 LE MASITINIB DANS LE TRAITEMENT DE LA DREPANOCYTOSE CETTE DÉCISION RENFORCE LA PROPRIÉTÉ INTELLECTUELLE DU [...]
ONWARD® Medical Publishes Closing of Bookbuild Offering
28/10/2024
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Oct. 28, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
IHA selects Cozeva as their sole analytics partner for all performance measurement programs
28/10/2024
Expanded partnership between IHA and Cozeva will implement redesign of flagship AMP program and drive healthcare quality and equity performance forward in California OAKLAND, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- [...]
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests
28/10/2024
28 October 2024 Announcement no. 19 BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests COPENHAGEN, DENMARK and BOSTON, MA, USA, October 28, 2024 (GLOBE NEWSWIRE) – [...]
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
28/10/2024
BERKELEY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- HOPO Therapeutics, Inc. announced today that it has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development [...]
Medicovestor, Inc. Announces Issuance/Approval of 3 Patents by the USPTO
28/10/2024
NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Medicovestor, Inc., a leading innovator in biotechnology, today announced the issuance of two new patents and the approval of an additional patent by the U.S. Patent and [...]
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
28/10/2024
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of [...]
VIVUS Shares Significant Regulatory Update on QSYMIA®
28/10/2024
- Postmarketing requirement fulfilled based on data demonstrating QYSMIA® reduces blood pressure - CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug Administration has [...]
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
28/10/2024
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN [...]
Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children’s Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia
28/10/2024
Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company [...]
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
28/10/2024
GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer [...]
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
28/10/2024
SUNNYVALE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today [...]
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
28/10/2024
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of [...]
Immunophotonics to Present at the 2024 ThinkEquity Conference
28/10/2024
ST. LOUIS, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, today announced that it will be [...]
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
28/10/2024
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “ [...]

Pages